Ikena Oncology is again shrinking its herd and signaling a tough fight ahead as one of two assets, a TEAD1-selective Hippo pathway inhibitor, is cut. The cancer biotech is laying off more than half of ...
ROCHESTER, N.Y. — One of Rochester’s largest employers, Paychex, is cutting its local workforce. The payroll company confirms what it calls a “reprioritization” of the company. A spokesperson for the ...
On Friday, Johnson & Johnson (NYSE:JNJ) announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults ...
One of Rochester’s largest employers, Paychex, Inc., laid off some employees last week. In an emailed statement, the company confirmed the move, writing: “We are continuously reprioritizing roles ...
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the strategic ...
Cellectar Biosciences (CLRB) announces a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform that delivers a broad array of therapeutic ...
I rate Rocket Pharmaceuticals a hold, given its strategic shift to late-stage AAV cardiovascular therapies and disciplined capital allocation. The company is cutting costs, reducing staff by 30%, and ...
Hosted on MSN
Mersana extends cash runway into mid-2026 as restructuring narrows focus to breast cancer
Marty Huber, CEO, announced a strategic restructuring and reprioritization plan that includes a "reduction of about 55% of our workforce across functions, the elimination of our internal pipeline ...
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results